scorecardresearch
Add as a preferred source on Google
Thursday, November 20, 2025
TopicInfluenza virus

Topic: influenza virus

‘Ease of administration, reduced hesitancy’ — India’s 1st nasal flu vaccine raises hope of acceptance

Mylab & Serum Institute of India launched Nasovac S4 last week. It's being seen as major step towards increasing acceptance of flu vaccines in India, where uptake has been low.

Govt’s disease-control body NCDC seeks report as ‘unknown fever’ surges in south India

The fever, which doctors describe as more severe than is usual in this season, mostly affecting children & adults with comorbidities. No life-threatening case so far, doctors say.

Fever & cough just won’t go away? Here’s why H3N2 is likely hitting Indians so hard

No. of H3N2 cases has doubled since last spike in 2021. Experts say low popularity of flu vaccines, comorbidities & allergens in air can be why people are becoming more susceptible to it.

2 dead in India from H3N2 influenza virus, 90 cases so far in country

One person died in Karnataka, the other in Haryana, according to reports.

On Camera

Why the US Congress put its foot down on releasing the Jeffrey Epstein files

The US House has effectively drawn a line in the sand and approved the release of the Epstein files despite President Trump's efforts to stop it from happening.

At Charcha 2025: Local entrepreneurship, not just big IT, will drive next wave of distributed AI work

While global corporations setting up GCCs in India continue to express confidence in availability of skilled AI engineers, the panel argued that India’s real challenge lies elsewhere.

Drone manufacturer ideaForge wins orders worth over Rs 100 crore from Army

ideaForge has formed a joint venture to manufacture and market UAVs in the US. Its Q6 UAV is now included in NATO and allied procurement systems.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.